Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Not yet recruiting 2

Sponsor Class

OTHER 2INDUSTRY 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 38Neoplasm Metastasis 9Brain Neoplasms 6Stomach Neoplasms 3Colorectal Neoplasms 3Advanced Breast Cancer 3Triple Negative Breast Neoplasms 2Recurrence 2Neoplasms 2Neoplasm, Residual 2Meningeal Carcinomatosis 2Esophageal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Cancer With Brain Metastasis 2Salivary Gland Neoplasms 1Rectal Neoplasms 1Ovarian Neoplasms 1Inflammatory Breast Neoplasms 1HER2-positive Breast Cancer 1HER2-negative Breast Cancer 1HER2 Overexpression 1Glioblastoma 1Gastric Adenocarcinoma 1Drug-Related Side Effects and Adverse Reactions 1Colonic Neoplasms 1Breast Cancer Metastatic 1Adenocarcinoma Of Esophagus 1

Interventions

Carboplatin 88pembrolizumab 85Paclitaxel 71Cyclophosphamide 63Capecitabine 38Doxorubicin 37Taxes 29130-nm albumin-bound paclitaxel 29Cisplatin 25Albumin-Bound Paclitaxel 22Epirubicin 21Drug Therapy 21Docetaxel 20sacituzumab govitecan 19olaparib 19camrelizumab 18atezolizumab 18Gemcitabine 17eribulin 16durvalumab 16Bevacizumab 16Radiotherapy 15toripalimab 14Specimen Handling 14Biopsy 13Everolimus 12Magnetic Resonance Spectroscopy 11apatinib 10Nivolumab 10talazoparib 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Triple Negative Breast Neoplasms × trastuzumab deruxtecan × Clear all
NCT07151586 2025-09-03

ALTER

UNICANCER

Phase 2 Not yet recruiting
260 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT05953168 2023-07-19

T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low Patients

Fudan University

Phase 2 Not yet recruiting
69 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡